Oncology Clinical Trials Market Top Players, Segments & Regional Trends By 2034
Straits Research released its highly anticipated report, “Global Oncology Clinical Trials Market Size & Outlook, 2026-2034.” According to the study, the market size is valued at USD 18.55 billion in 2025 and is anticipated to grow to USD 38.23 billion by 2034, registering a compound annual growth rate (CAGR) of 8.41%.
Market Dynamics
The market growth is primarily attributed to the increasing prevalence of cancer worldwide is driving the demand for more oncology clinical trials to develop effective therapies. For example, in February 2024, as per the WHO, global cancer cases are projected to rise to over 35 million annually by 2050, emphasizing the urgent need for new treatments and clinical research. This rising incidence of cancer fuels the demand for innovative clinical trials, supporting the growth of the oncology clinical trials market. Moreover, the establishment of new oncology research centers and improvements in clinical trial infrastructure in emerging markets is creating new opportunities in the field. For example, in April 2025, as per the National Library of Medicine, in 2024, China's National Medical Products Administration (NMPA) launched initiatives to simplify trial approvals and increase the number of qualified trial sites, encouraging more international oncology studies in the region. Such expansion provides cost-effective trial options and access to larger patient pools, boosting global oncology clinical trial activities.
Market Highlights
-
Phase: The Phase I segment dominated the market in 2025 with a revenue share of 35.26%.
Type: The Prostate Cancer segment is expected to witness the highest CAGR (9.12%), owing to the increasing prevalence of prostate cancer among aging male populations and the rising focus on developing targeted therapies.
Study: The Interventional Studies segment dominated the market in 2025, with a revenue share of 75.63%.
Regional Insights: North America dominates the market in 2025, with a 47.92% share, fuelled by advanced clinical research infrastructure and a growing patient pool.
Hoffmann-La Roche Ltd AstraZeneca Merck & Co., Inc. Gilead Sciences, Inc PARAXEL International Corporation ICON plc Syneos Health Medpace Novotech Charles River Laboratories Laboratory Corporation of America Holdings Pfizer Inc. Lilly USA, LLC Novartis AG Bristol-Myers Squibb Company AbbVie Inc. Amgen Inc. Sanofi GSK plc. Bayer AG Others Recent Developments Segmentation
By Phase (2026-2034) Phase I Phase II Phase III Phase IV By Type (2026-2034) Breast Cancer Melanoma Cancer Colorectal Cancer Prostate Cancer Lung Cancer Others By Study (2026-2034) Interventional studies Observational studies Expanded access studies Want to see full report on
Oncology Clinical Trials Market Full Report
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment